Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509

Lanphear, 1992, Latent period for malignant mesothelioma of occupational origin, J Occup Med, 34, 718

Price, 2009, Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005, Crit Rev Toxicol, 39, 576, 10.1080/10408440903044928

Peto, 1999, The European mesothelioma epidemic, Br J Cancer, 79, 666, 10.1038/sj.bjc.6690105

Kao, 2010, Malignant mesothelioma, Intern Med J, 40, 742, 10.1111/j.1445-5994.2010.02223.x

Hodgson, 2005, The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050, Br J Cancer, 92, 587, 10.1038/sj.bjc.6602307

Martini, 1987, Pleural mesothelioma, Ann Thorac Surg, 43, 113, 10.1016/S0003-4975(10)60182-8

Van Meerbeeck, 2005, J Clin Oncol, 23, 6881, 10.1200/JCO.20005.14.589

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Ohta, 1999, VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours, Br J Cancer, 81, 54, 10.1038/sj.bjc.6690650

Strizzi, 2001, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol, 193, 468, 10.1002/path.824

Masood, 2003, Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops, Int J Cancer, 104, 603, 10.1002/ijc.10996

Demirag, 2005, Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma, Chest, 128, 3382, 10.1378/chest.128.5.3382

Kumar-Singh, 1999, Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression, J Pathol, 189, 72, 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0

Konig, 2000, Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma, Respiration, 67, 36, 10.1159/000029460

Edwards, 2001, Angiogenesis is an independent prognostic factor in malignant mesothelioma, Br J Cancer, 85, 863, 10.1054/bjoc.2001.1997

Heckman, 2008, The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis, Cancer Res, 68, 4754, 10.1158/0008-5472.CAN-07-5809

Wedge, 2005, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 65, 4389, 10.1158/0008-5472.CAN-04-4409

Drevs, 2007, Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors, J Clin Oncol, 25, 3045, 10.1200/JCO.2006.07.2066

Ryan, 2007, Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC), Invest New Drugs, 25, 445, 10.1007/s10637-007-9050-y

Yamamoto, 2009, Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors, Cancer Chemother Pharmacol, 64, 1165, 10.1007/s00280-009-0979-8

Matulonis, 2009, Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer, J Clin Oncol, 27, 5601, 10.1200/JCO.2009.23.2777

Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann.Oncol, 15, 257, 10.1093/annonc/mdh059

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Janne, 2006, Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program, J Thorac Oncol, 1, 506, 10.1016/S1556-0864(15)30351-8

Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J Clin Oncol, 26, 1698, 10.1200/JCO.2006.09.9887

Garland, 2007, Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study, J Clin Oncol, 25, 2406, 10.1200/JCO.2006.09.7634

Jackman, 2008, Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma, Cancer, 113, 808, 10.1002/cncr.23617

Mathy, 2005, Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, 50, 83, 10.1016/j.lungcan.2005.04.010

Jahan, 2010, Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107), J Clin Oncol, 24

Janne, 2010, Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307), J Clin Oncol, 25

Nowak, 2008, Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM), J Clin Oncol, 26

Jackman, 2008, Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma, Cancer, 113, 808, 10.1002/cncr.23617

Karrison, 2007, Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabin/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioms (MM), J Clin Oncol, 25, 7526, 10.1200/jco.2007.25.18_suppl.7526

van Klaveren, 2004, Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma, Lung Cancer, 43, 63, 10.1016/S0169-5002(03)00292-7

Hofmann, 2009, Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model, Neoplasia, 11, 812, 10.1593/neo.09662

Klosowska-Wardega, 2009, Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma, PLoS One, 4, e8149, 10.1371/journal.pone.0008149

Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med, 10, 145, 10.1038/nm988

Dickson, 2007, Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy, Clin Cancer Res, 13, 3942, 10.1158/1078-0432.CCR-07-0278

Pietras, 2003, STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake, Clin Cancer Res, 9, 3779

Pietras, 2002, Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy, Cancer Res, 62, 5476

Pietras, 2001, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors, Cancer Res, 61, 2929

Goss, 2009, Eur.J Cancer, 45, 782, 10.1016/j.ejca.2008.10.022

Laurie, 2008, J Clin Oncol, 26, 1871, 10.1200/JCO.2007.14.4741

Goss, 2010, Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study, J Clin Oncol, 28, 49, 10.1200/JCO.2009.22.9427